Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O43921

UPID:
EFNA2_HUMAN

ALTERNATIVE NAMES:
EPH-related receptor tyrosine kinase ligand 6; HEK7 ligand

ALTERNATIVE UPACC:
O43921; O76020

BACKGROUND:
Ephrin-A2 serves as a crucial ligand for Eph receptors, engaging in cell-to-cell communication essential for development and tissue patterning. It plays a significant role in bidirectional signaling, affecting cell migration, adhesion, and repulsion. This protein's interaction with the EPHA2 receptor suggests a vital function in the regulation of bone remodeling, influencing both the formation and resorption of bone.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ephrin-A2 offers a promising avenue for developing novel therapeutic approaches, especially for conditions affecting bone health and developmental processes in the nervous and vascular systems.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.